sarah Chorley, Author at Cycle Vita

New drug, TASCENSO ODT® (fingolimod), launched to meet the needs of multiple sclerosis patients in the US left without essential patient support

TASCENSO ODT is available to dispense to US multiple sclerosis (MS) patients. It is bioequivalent to, but not a generic of, Gilenya® (fingolimod) capsules. On March 31st 2023 the Gilenya patient support program will be withdrawn.

Multiple sclerosis patients in US left without essential patient support program will now receive equivalent backing from Cycle Pharmaceuticals following FDA’s approval of TASCENSO ODT^® (fingolimod)

Cycle Pharmaceuticals Ltd (Cycle) is pleased to announce its intention to commercialize TASCENSO ODT® (fingolimod) in the US multiple sclerosis (MS) market in Q1 2023.
Eligible patients will receive full MS patient support program through Cycle Vita™

Cycle Pharmaceuticals to launch TASCENSO ODT® (fingolimod) in US in Q1 2023

Cycle Pharmaceuticals Ltd (Cycle) is pleased to announce its intention to commercialize TASCENSO ODT® (fingolimod) in the US multiple sclerosis (MS) market in Q1 2023.
Eligible patients will receive full MS patient support program through Cycle Vita™